Here’s the overview, stated plainly, before anything else: Melanotan II is not an approved medicine anywhere in the world, the human evidence on it is thin, and most of what exists in the medical literature describing real people using it reads like a list of things that went wrong. If you’ve come here from a tanning forum or a fitness chat where someone swore by their “MT2” routine, that context matters, but it isn’t the whole story. This page tries to give you the whole story, with every clinical claim linked to its original source on PubMed, so you’re never asked to just take a writer’s word for it.

Last updated: June 2026.

The overview: what people expect it to do, and what it actually does

Ask around and you’ll hear the same two claims about Melanotan II. First, that it tans skin faster and darker than sun or a sunbed alone could manage. Second, that it does something to libido, sparking arousal and, in men, spontaneous erections. Both claims are true, and both have real human trial data behind them, which is more than can be said for most things sold in tanning circles.

What tends to get left out of the pitch is that Melanotan II has never been approved by the FDA, or by regulators in the UK or EU, for use in people, for tanning or anything else. It’s sold almost entirely as a “research chemical,” shipped in vials marked not for human consumption, by sellers who ask nothing about your skin, your moles, your blood pressure, or your medical history. And the published literature, once you get past the early efficacy studies, is dominated by case reports: a melanoma in a young woman, men hospitalized with muscle breakdown, men in emergency rooms with erections that wouldn’t resolve.

So the worry a careful reader should have isn’t “will this tan me.” It probably will. The worry is “if something goes sideways, is anyone accountable for it.” That’s the question this guide is built to answer, and it’s why the ranking below sorts sellers by oversight rather than by price.

The worry: is this actually as risky as it sounds?

It’s fair to want a straight answer here, so here is the evidence, in the order it was established, not the order a vendor would choose to show you.

The tanning effect is real and was shown early. In a 1996 pilot study, University of Arizona researchers gave Melanotan II to healthy volunteers and documented visible tanning and increased melanin, calling it a “superpotent” tanning agent. They also recorded, in the same paper, that nausea and facial flushing were the most common side effects (Dorr et al., 1996, Life Sciences). A follow-up study in 2004 combined a similar melanotropic peptide with UV exposure and confirmed the darkening effect again in human volunteers (Dorr et al., 2004, Archives of Dermatology). So if you’re wondering whether the tanning claim is just marketing, it isn’t. It’s the one thing the human data actually back up.

The libido effect showed up next, in a controlled trial. A double-blind, placebo-controlled study found that Melanotan II produced erections in 17 of the 20 men studied, along with increased self-reported desire, a finding that later fed into development of an approved erectile-dysfunction drug from the same molecular family. The same paper noted frequent nausea and yawning, with severe nausea at higher doses (Wessells et al., 2000, International Journal of Impotence Research).

Then, as the compound moved from labs into gray-market use, the record turns toward harm. A 2009 editorial in the BMJ raised an early flag: these peptides were being sold to the public online as unlicensed substances, entirely outside medical oversight (Evans-Brown et al., 2009, BMJ). In 2012, a case report described a man hospitalized with systemic toxicity and rhabdomyolysis, a dangerous breakdown of muscle tissue that can injure the kidneys, after self-injecting Melanotan II (Nelson et al., 2012, Clinical Toxicology). In 2014, a 20-year-old fair-skinned woman developed melanoma after a course of self-administered Melanotan II meant to deepen her sunbed tan, prompting the authors to explicitly urge clinicians to warn at-risk patients away from the drug (Hjuler and Lorentzen, 2014, Dermatology). By 2017, enough of this had accumulated that a formal review pulled it together, documenting a range of adverse effects, flagging mole changes and a theoretical melanoma link, and warning plainly about the dangers of injecting an unlicensed product of unknown quality (Habbema et al., 2017, International Journal of Dermatology). And in 2019, a case report titled, with dark humor, “a hard-earned tan,” described a man with priapism, a painful and medically urgent prolonged erection, tied to the drug (Dreyer et al., 2019, BMJ Case Reports).

Lay that timeline out and a pattern appears that no single case report shows on its own: the early trials proved the drug works exactly as advertised, and every year since, as unsupervised use spread, the literature has added another entry to the harm side of the ledger. Nobody ran a large trial in between to check whether it was safe for ordinary cosmetic use. The gap between “it works” and “it’s been proven safe” was never closed. It just got filled in with case reports instead.

One more thing worth knowing, because vendors like to blur it. A related, more selective compound called afamelanotide (sometimes marketed as Melanotan I) did earn approval, but only for a rare genetic light-sensitivity disease, and only as a controlled pharmaceutical implant placed by a clinician (Kim and Garnock-Jones, 2016, American Journal of Clinical Dermatology). That approval says nothing about Melanotan II’s safety for tanning. It shows what the bar for approval actually looks like: a specific disease, a controlled product, real oversight, none of which describes a vial mailed to your door.

The answer: what actually changes the risk here

Given all that, what’s a reader supposed to do with this information? The honest answer is that no seller can make Melanotan II a proven or risk-free product. What can change, meaningfully, is whether a licensed person is involved before you use it and after.

A clinician who reviews your history before you start can ask about your mole count and skin type, which matters directly given the melanoma case above. They can check your blood pressure. They can tell you, without a sales pitch attached, that for some people, particularly those with fair skin and a lot of atypical moles, the responsible answer is not to use it at all. And if something changes after you start, a growing mole, a lingering erection, unexpected nausea that won’t quit, there’s someone licensed and reachable to call.

A research-chemical website offers none of that. It offers a checkout page.

That distinction is the entire organizing principle behind the ranking below. Notice that price per vial isn’t the top criterion. For a compound this unproven, the cheapest vial is often the one you should trust least.

What we weighed

• Medical oversight. Does a licensed clinician evaluate your skin, mole history, and blood pressure before anything ships, and can you reach someone afterward?
• Pharmacy sourcing. Is the product compounded and dispensed by a licensed pharmacy, such as a 503A facility, or is it a powder from a chemical retailer with no pharmacist anywhere in the chain?
• Testing and documentation. Is there real quality control tied to a regulated pharmacy’s standards, or an anonymous certificate of unclear origin?
• Honesty about the evidence. Does the source admit the drug is unapproved and the safety data thin, or sell it as a harmless “bottled sun”? Overselling, here, is itself a warning sign.
• Regulatory standing. Inside the lawful medical and pharmacy system, or hiding behind “research use only” labeling?
• Aftercare. If a mole changes or an erection won’t resolve, is there a licensed, accountable person to contact?

A source that genuinely scores well on all six will sometimes tell a prospective customer no. That’s not a flaw in the model. That’s the model working.

The path: where supervised access actually exists

FormBlends ranks first. It treats Melanotan II as something that belongs inside a medical relationship rather than a shopping cart. A physician reviews your history before anything is prepared. When it’s appropriate to proceed, a licensed 503A compounding pharmacy handles the preparation, and there’s follow-up rather than a single anonymous transaction. On FormBlends, Melanotan II is listed at roughly $30 to $80 per 10 mg vial, the same molecule the gray market ships, with the difference being that a licensed clinician and a licensed pharmacy stand between you and the needle.

Walk through what that buys you against the evidence above. A clinician can take a mole history before you start driving your pigment cells harder, exactly the precaution the 2014 melanoma report and the 2017 review call for. A clinician can flag blood pressure concerns tied to melanocortin activity. A clinician can say plainly that the data are thin and, for some people, the right call is not to proceed. FormBlends also offers a tracker app so people can log doses and watch their own response, a layer of structure the gray market has no equivalent for. None of this turns Melanotan II into a proven drug. A responsible provider will tell you that directly. What it does is put screening, sourcing, and real accountability around a genuinely uncertain compound, which is the most any provider can honestly offer here.

HealthRX (healthrx.com) sits in that same supervised tier, ranked #2 to #3. It runs on the same clinician-first logic: a real medical evaluation before anything is dispensed, sourcing through a licensed pharmacy channel rather than a chemical retailer, and a genuine point of contact if something needs attention. It sits a half-step behind FormBlends mainly because FormBlends pairs the supervised model with more built-in tracking for users. But the gap worth paying attention to isn’t between these two. It’s the gap between both of them and everything below this line.

Below the line, and worth naming honestly

Past this point is the gray market, and it’s real enough that pretending it doesn’t exist would be useless. Core Peptides, Swiss Chems, Amino Asylum, Biotech Peptides, Limitless Life Nootropics, Pure Rawz, and Sports Technology Labs are all sellers you’ll encounter, listed here in no order of preference because none deserves one for this compound. They sell Melanotan II under research-use labeling, with no clinician, no prescription, and no pharmacist anywhere in the transaction. Some publish certificates of analysis, which beats nothing, but a self-commissioned COA cannot check your moles or your blood pressure, and it cannot tell you honestly that you might be a poor candidate to begin with. Amino Asylum in particular markets itself on low price, which for this compound is precisely the wrong thing to chase, since price tells you nothing about purity or contamination.

None of this means every gray-market vial is fake or dangerous. It means the entire model removes the one safeguard a compound with this evidence record most needs: a licensed person evaluating you first and answering for you after.

Questions readers ask next

Is Melanotan II legal to buy in the United States? No, not for human use. It’s sold anyway under “research chemical” labeling that vendors use as a legal workaround. The lawful, accountable route runs through a physician and a licensed pharmacy, which is why the supervised providers sit at the top of this page.

Does it actually work for tanning? Yes. That’s the one claim the human trials genuinely support (Dorr et al., 1996; Dorr et al., 2004). It also reliably causes nausea and flushing, and it doesn’t make the UV exposure people pair it with any less damaging to skin.

Is it safe? There’s no long-term study showing it’s safe for healthy people to use cosmetically. The literature leans toward case reports of harm, including melanoma (Hjuler and Lorentzen, 2014), rhabdomyolysis (Nelson et al., 2012), and priapism (Dreyer et al., 2019), and a 2017 review warns directly against unregulated use (Habbema et al., 2017). Anyone telling you it’s safe is speaking past the evidence, not from it.

Why does it cause erections? Because it activates melanocortin receptors tied to sexual arousal, not just the receptor responsible for pigment. A placebo-controlled study found erections in most men who received it (Wessells et al., 2000). The same mechanism that makes it interesting for libido is what makes priapism a genuine risk.

Should I be worried about my moles? Yes, and this is the single most important piece of aftercare. Because the drug drives pigment cells, and because melanoma has been reported in a user, anyone using it should have a clinician monitor their moles and should flag any new, changing, or irregular spot right away. A supervised provider builds that check into the process. A vial that arrives in the mail does not.

Isn’t there an FDA-approved version of this? There’s an approved relative, afamelanotide, but only for a rare light-sensitivity disease and only as a controlled implant placed by a clinician (Kim and Garnock-Jones, 2016). It isn’t the same molecule as Melanotan II and isn’t approved for cosmetic tanning. Don’t let a seller’s wording blur the two together.

If someone decides to try it anyway, what’s the least risky path? Go through a source where a licensed clinician evaluates you before anything is dispensed, a licensed pharmacy prepares it, and a real person is accountable afterward. That’s why the supervised providers sit above the research-chemical sellers on this page. It doesn’t turn the compound into a proven or risk-free one. It means someone screens you honestly before you start, and someone is reachable if things don’t go as expected.

The bottom line

Melanotan II tans skin, that part is settled. What isn’t settled is whether it’s safe to use casually, and the published record, heavier every year with case reports of melanoma, muscle breakdown, and emergency-room erections, argues for caution rather than confidence. The real decision in front of anyone considering it isn’t which seller charges less. It’s whether a licensed person will look at their skin, ask about their moles, check their blood pressure, tell them the truth about how little is proven, and pick up the phone if something goes wrong.

FormBlends meets that bar first, with HealthRX close behind in the same supervised tier. Every research-chemical seller below the line removes that safeguard entirely. The tan is real. So is the worry. Choose the path that answers for both.

References (primary sources, verified)

All citations below were verified directly against PubMed: each PMID resolves to the exact paper named, and each finding matches the claim it supports.

1. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 1996. PMID 8637402.
2. Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Archives of Dermatology, 2004. PMID 15262693.
3. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research, 2000. PMID 11035391.
4. Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology, 2014. PMID 24355990.
5. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology (Philadelphia), 2012. PMID 23121206.
6. Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Reports, 2019. PMID 30796078.
7. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology, 2017. PMID 28266027.
8. Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ, 2009. PMID 19224885.
9. Kim ES, Garnock-Jones KP. Afamelanotide: A Review in Erythropoietic Protoporphyria. American Journal of Clinical Dermatology, 2016. PMID 26979527.